Moderna shares surge 85% premarket after successful final-stage mRNA cancer vaccine trial

Published Aug 19, 12:34 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

Moderna's stock skyrocketed by 85% in premarket trading on August 19, 2026, heading toward its best-ever trading day, after the company announced positive results from the first successful final-stage study of an experimental mRNA-based cancer vaccine. This marks the first successful late-stage trial for any mRNA cancer therapy, nearly doubling the biotech giant's share price and surging over 100% earlier in the morning. The development represents a major milestone for mRNA technology beyond COVID-19 vaccines.

Source

Forbes - BusinessWestern

Original headline: Moderna Shares Skyrocket 85% Toward Best Day Ever—On Success Of Cancer Drug Trial

Original language: EN-US